Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Poliomyelitis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    128 result(s) found for: Poliomyelitis. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2015-003544-39 Sponsor Protocol Number: M3-ABMG Start Date*: 2015-10-21
    Sponsor Name:FIDEC - Fighting Infectious Diseases in Emerging Countries
    Full Title: A Phase 4 study to evaluate the safety and immunogenicity of monovalent oral polio vaccine type 2 in healthy IPV-vaccinated children aged 1 to 5 years in Lithuania
    Medical condition: evaluation of safety of SABIN mOPV2 in healthy IPV-vaccinated children of 1 – 5 years of age (Polio disease)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10036016 Poliomyelitis NOS LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: View results
    EudraCT Number: 2008-006124-64 Sponsor Protocol Number: 111815 (DTPA-IPV(BOOSTRIX-IPV)-010 Start Date*: 2009-02-12
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, open-label, randomised, multicentre study to evaluate the immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals’ dTpa-IPV vaccine (Boostrix Polio) compared with S...
    Medical condition: Booster immunisation of healthy preschool children against diphtheria, tetanus, pertussis, poliomyelitis, mumps, measles and rubella; and first or second immunisation of healthy preschool children ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10034738 LLT
    9.1 10013023 LLT
    9.1 10043376 LLT
    9.1 10036012 LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000943-26 Sponsor Protocol Number: 115375 Start Date*: 2011-05-12
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IV, open-label, study to assess the antibody persistence in healthy 5-year-old children, previously vaccinated at 3, 5 and 11months of age with GSK Biologicals’ DTPa-HBV-IPV/Hib or DTPa-IPV...
    Medical condition: Healthy volunteers (Immunogenicity of the DTPa-HBV-IPV/Hib and DTPa-IPV/Hib vaccines in terms of persistence of antibodies to diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and Hib vacc...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10043376 Tetanus PT
    13.1 10021881 - Infections and infestations 10018952 Haemophilus influenzae infection LLT
    13.1 10021881 - Infections and infestations 10034738 Pertussis PT
    13.1 10021881 - Infections and infestations 10019731 Hepatitis B PT
    13.1 10021881 - Infections and infestations 10013023 Diphtheria PT
    13.1 10021881 - Infections and infestations 10036012 Poliomyelitis PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2009-012219-16 Sponsor Protocol Number: 113060 Start Date*: 2011-04-18
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IV, open-label, non-randomised, multicentre study to assess the immunogenicity and reactogenicity of a booster dose of GSK Biologicals’ combined reduced-antigen-content diphtheria-tetanus, ...
    Medical condition: Booster immunisation of healthy adults against diphtheria, tetanus, pertussis and poliomyelitis.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10043376 Tetanus PT
    14.0 10021881 - Infections and infestations 10034738 Pertussis PT
    14.0 10021881 - Infections and infestations 10013023 Diphtheria PT
    14.0 10021881 - Infections and infestations 10036012 Poliomyelitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005188-17 Sponsor Protocol Number: IPV30 Start Date*: 2015-11-19
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of different sequential schedules of Inactivated Poliomyelitis Vaccine (IMOVAX Polio®) followed by Oral Poliomyelitis Vaccine in Healthy Infants in China versus Oral Polio...
    Medical condition: Poliomyelitis
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-004056-36 Sponsor Protocol Number: Sched2 Start Date*: 2007-12-20
    Sponsor Name:Health Protection Agency
    Full Title: A Phase IV, randomised study to evaluate the immune response of UK infants receiving DTaP/Hib/IPV, meningococcal C conjugate and pneumococcal conjugate vaccines, antibody persistence and responses ...
    Medical condition: All products arre vaccines and are given to healthy volunteers to induce immunological responses to provide protection against: Pediacel - tetanus, diphtheria, polio, pertussis (whooping cough), H...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027274 Meningococcal infection PT
    9.1 10061353 Pneumococcal infection LLT
    9.1 10013023 Diphtheria LLT
    9.1 10043376 Tetanus LLT
    9.1 10034738 Pertussis LLT
    9.1 10018955 Haemophilus meningitis LLT
    9.1 10036008 Polio LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-005196-24 Sponsor Protocol Number: TD9809-LT Start Date*: 2015-11-19
    Sponsor Name:Sanofi Pasteur Limited
    Full Title: Three-, Five-, and Ten-Year Data on the Long-Term Immunogenicity of Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and Inactivated Poliomyelitis Vaccine (TdcP-IPV...
    Medical condition: Pertussis Tetanus Diphtheria Poliomyelitis Hepatitis B
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-012460-14 Sponsor Protocol Number: 112980 Start Date*: 2010-05-03
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, open-label, randomised study to assess the safety and immunogenicity of a birth dose of GSK Biologicals’ reduced-antigen-content tri-component pertussis vaccine followed by routine paed...
    Medical condition: Primary and booster immunisation of healthy infants in the first two years of life against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, Haemophilus influenzae type b, rotavirus and p...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10043376 Tetanus LLT
    12.1 10013023 Diphtheria LLT
    12.1 10034738 Pertussis LLT
    12.1 10019731 Hepatitis B LLT
    12.1 10036012 Poliomyelitis LLT
    12.1 10018952 Haemophilus influenzae infection LLT
    12.1 10067470 Rotavirus infection LLT
    12.1 10061353 Pneumococcal infection LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) GB (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016635-36 Sponsor Protocol Number: 113615 Start Date*: 2010-03-04
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, open-label, randomised, multicentre study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib-MenC-TT vaccine, when given to healthy infants at 2,...
    Medical condition: Primary and booster immunisation of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, Haemophilus influenzae type b, serogroup C meningoc...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10043376 Tetanus LLT
    12.1 10013023 Diphtheria LLT
    12.1 10034738 Pertussis LLT
    12.1 10019731 Hepatitis B LLT
    12.1 10036012 Poliomyelitis LLT
    12.1 10018952 Haemophilus influenzae infection LLT
    12.1 10027274 Meningococcal infection LLT
    12.1 10067470 Rotavirus infection LLT
    12.1 10061353 Pneumococcal infection LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004458-25 Sponsor Protocol Number: RVX01C Start Date*: Information not available in EudraCT
    Sponsor Name:Sanofi Pasteur MSD
    Full Title: Antibody persistence in 11 to 13-year-old children previously vaccinated at 6 years old with either REVAXIS or DT Polio, and immune response to a booster dose of TETRAVAC-ACELLULAIRE
    Medical condition: Persistence of antibody against diphtheria, tetanus and poliomyelitis in 11 to 13-year-old children who received either REVAXIS or DT Polio at 6 year of age, and immune response to TETRAVAC-ACELLUL...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10054175 Polio immunisation PT
    14.0 10042613 - Surgical and medical procedures 10054129 Diphtheria immunisation PT
    14.0 10042613 - Surgical and medical procedures 10069577 Pertussis immunisation PT
    14.0 10042613 - Surgical and medical procedures 10054131 Tetanus immunisation PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-000876-33 Sponsor Protocol Number: 114843 Start Date*: 2011-08-16
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, double-blind, multicentre study to evaluate the safety and immunogenicity of a booster dose of new formulations of GlaxoSmithKline Biologicals’ combined DTPa-HBV-IPV/Hib vaccine in heal...
    Medical condition: Healthy volunteers (toddlers): Booster immunization against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b (Hib) diseases.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10043376 Tetanus PT
    14.0 10021881 - Infections and infestations 10018952 Haemophilus influenzae infection LLT
    14.0 10021881 - Infections and infestations 10034738 Pertussis PT
    14.0 10021881 - Infections and infestations 10019731 Hepatitis B PT
    14.0 10021881 - Infections and infestations 10013023 Diphtheria PT
    14.0 10021881 - Infections and infestations 10036012 Poliomyelitis PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-021569-58 Sponsor Protocol Number: 113948 Start Date*: 2010-11-17
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase I/II, double-blind, randomized, multicentre study to evaluate the safety and immunogenicity of new formulations of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib vaccine when administered to...
    Medical condition: Primary immunization of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b (Hib) diseases.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10043376 Tetanus PT
    13.1 10021881 - Infections and infestations 10018952 Haemophilus influenzae infection LLT
    13.1 10021881 - Infections and infestations 10034738 Pertussis PT
    13.1 10021881 - Infections and infestations 10019731 Hepatitis B PT
    13.1 10021881 - Infections and infestations 10013023 Diphtheria PT
    13.1 10021881 - Infections and infestations 10036012 Poliomyelitis PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2015-005184-16 Sponsor Protocol Number: IPV26 Start Date*: 2015-11-17
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of Fractional Booster Dose of sanofi pasteur’s Inactivated Poliomyelitis Vaccine (IMOVAX Polio) Administered Intradermally versus Full Booster Dose of Inactivated Poliomye...
    Medical condition: Poliomyelitis
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-005183-42 Sponsor Protocol Number: IPV25 Start Date*: 2015-11-17
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of Fractional Doses of Sanofi Pasteur’s Inactivated Poliomyelitis Vaccine (IMOVAX Polio™) Administered Intradermally versus Full Doses of Inactivated Poliomyelitis Vaccine...
    Medical condition: Poliomyelitis
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-000052-29 Sponsor Protocol Number: VIPV-04 Start Date*: 2014-09-17
    Sponsor Name:Statens Serum Institut
    Full Title: Safety and immunogenicity of 3 adjuvated reduced dose inactivated poliovirus vaccines (IPV-Al SSI) and non-adjuvated full dose IPV SSI, given as a booster vaccination to adolescents with a hi...
    Medical condition: Profylactic immunisation against poliomyelitis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10054187 Polio immunization LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-005182-23 Sponsor Protocol Number: IPV13 Start Date*: 2015-11-17
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of the Inactivated Poliomyelitis Vaccine (IMOVAX Polio™) Administered at 2, 3, and 4 Months of Age and Followed by a Booster Dose at 18 Months of age in Healthy Infants in...
    Medical condition: Poliomyelitis
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-023086-21 Sponsor Protocol Number: RPV04C Start Date*: 2010-12-13
    Sponsor Name:Sanofi Pasteur MSD S.N.C.
    Full Title: An open-label, multicentre study to evaluate the immunogenicity and safety of one dose of a diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (REPEVAX®) followed by 2 doses of a di...
    Medical condition: Evaluation of the immunogenicity and safety of one dose of a diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (REPEVAX®) followed by 2 doses of a diphtheria, tetanus and poliomyel...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10042613 - Surgical and medical procedures 10054129 Diphtheria immunisation PT
    13.1 10042613 - Surgical and medical procedures 10053386 Poliomyelitis vaccine LLT
    13.1 10042613 - Surgical and medical procedures 10069577 Pertussis immunisation PT
    13.1 10042613 - Surgical and medical procedures 10054131 Tetanus immunisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001608-32 Sponsor Protocol Number: 112683 Start Date*: 2017-11-14
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open-label study to assess the safety and reactogenicity of GlaxoSmithKline Biologicals’ Inactivated Poliomyelitis Vaccine Poliorix administered as a booster dose at 18-24 months of age in healt...
    Medical condition: Healthy volunteers (Poliomyelitis)
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-006686-37 Sponsor Protocol Number: SH600009 Start Date*: 2022-02-18
    Sponsor Name:Sanofi Pasteur
    Full Title: Immunogenicity and Safety of a DTwP-HepB-Hib-IPV (SHAN6™) Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers in Thailand
    Medical condition: Diphtheria, Tetanus, Pertussis, Hepatitis-B, invasive Haemophilus influenzae type b and Poliomyelitis diseases
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10069577 Pertussis immunisation PT
    21.1 10042613 - Surgical and medical procedures 10054129 Diphtheria immunisation PT
    21.1 10042613 - Surgical and medical procedures 10054175 Polio immunisation PT
    21.1 10042613 - Surgical and medical procedures 10054181 Hepatitis B immunization LLT
    21.1 10042613 - Surgical and medical procedures 10069533 Haemophilus influenzae type b immunisation PT
    21.1 10042613 - Surgical and medical procedures 10054131 Tetanus immunisation PT
    21.1 10042613 - Surgical and medical procedures 10076886 Rotavirus immunisation PT
    21.1 10042613 - Surgical and medical procedures 10069578 Pneumococcal immunisation PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-001446-16 Sponsor Protocol Number: F05-TdI-301 Start Date*: 2006-12-01
    Sponsor Name:Sanofi Pasteur MSD
    Full Title: Comparison of the immunogenicity and safety of a combined adsorbed low dose diphtheria, tetanus and inactivated poliomyelitis vaccine (REVAXIS®) with a combined diphtheria, tetanus and inactivated ...
    Medical condition: Not applicable - Healthy volunteers - 6 year-old child
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 18 18:12:08 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA